Carolina Rosadas explains why we need more research investigating human T lymphotropic virus type 1 (HTLV-1) infections, and why more public visibility is needed for those affected.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Poiesz, B. J., Ruscetti, F. W., Reitz, M. S., Kalyanaraman, V. S. & Gallo, R. C. Nature 294, 268–271 (1981).
Schierhout, G. et al. Lancet Infect. Dis. 20, 133–143 (2019).
Rosadas, C. et al. PLoS Negl. Trop. Dis. 14, e0008761 (2020).
Human T-lymphotropic Virus Type 1: Technical Report (WHO, 2021).
Rosadas, C., Malik, B., Taylor, G. P. & Puccioni-Sohler, M. PLoS Negl. Trop. Dis. 12, e0006913 (2018).
Rosadas, C. et al. Lancet Glob. Health 11, E781–E790 (2023).
Gessain, A., Ramassamy, J.-L., Afonso, P. V. & Cassar, O. Front. Immunol. 14, 1043600 (2023).
Einsiedel, L. et al. BMC Public Health 16, 787 (2016).
Rosadas, C. & Taylor, G. P. Lancet Microbe 3, E164 (2022).
International Health Policy Forum for the Elimination of HTLV: Advancing HTLV Health Policies around the World (PAHO, 2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Supplementary information
Supplementary Information
Portuguese translation.
Rights and permissions
About this article
Cite this article
Rosadas, C. Making HTLV-1 and those affected visible. Nat Microbiol 9, 880–881 (2024). https://doi.org/10.1038/s41564-024-01652-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41564-024-01652-7
